FSTL3 and ischemic disease: Indeed, the findings of the present study demonstrate an important role of FSTL3 in iPS‐ECs, and in the early stages of EC differentiation, which may be significant toward our aim of generating therapeutically relevant ECs for use in both regenerative medicine and treatment of ischemic diseases.